Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

83 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
A phase I study of the SRC kinase inhibitor dasatinib with trastuzumab and paclitaxel as first line therapy for patients with HER2-overexpressing advanced breast cancer. GEICAM/2010-04 study.
Ocana A, Gil-Martin M, Martín M, Rojo F, Antolín S, Guerrero Á, Trigo JM, Muñoz M, Pandiella A, Diego NG, Bezares S, Caballero R, Carrasco E, Urruticoechea A. Ocana A, et al. Among authors: urruticoechea a. Oncotarget. 2017 Apr 14;8(42):73144-73153. doi: 10.18632/oncotarget.17113. eCollection 2017 Sep 22. Oncotarget. 2017. PMID: 29069857 Free PMC article.
Autophagy-related gene 12 (ATG12) is a novel determinant of primary resistance to HER2-targeted therapies: utility of transcriptome analysis of the autophagy interactome to guide breast cancer treatment.
Cufí S, Vazquez-Martin A, Oliveras-Ferraros C, Corominas-Faja B, Urruticoechea A, Martin-Castillo B, Menendez JA. Cufí S, et al. Among authors: urruticoechea a. Oncotarget. 2012 Dec;3(12):1600-14. doi: 10.18632/oncotarget.742. Oncotarget. 2012. PMID: 23307622 Free PMC article.
Phase I clinical trial of nintedanib plus paclitaxel in early HER-2-negative breast cancer (CNIO-BR-01-2010/GEICAM-2010-10 study).
Quintela-Fandino M, Urruticoechea A, Guerra J, Gil M, Gonzalez-Martin A, Marquez R, Hernandez-Agudo E, Rodriguez-Martin C, Gil-Martin M, Bratos R, Escudero MJ, Vlassak S, Hilberg F, Colomer R. Quintela-Fandino M, et al. Among authors: urruticoechea a. Br J Cancer. 2014 Sep 9;111(6):1060-4. doi: 10.1038/bjc.2014.397. Epub 2014 Jul 24. Br J Cancer. 2014. PMID: 25058346 Free PMC article. Clinical Trial.
A phase Ib study of sonidegib (LDE225), an oral small molecule inhibitor of smoothened or Hedgehog pathway, in combination with docetaxel in triple negative advanced breast cancer patients: GEICAM/2012-12 (EDALINE) study.
Ruiz-Borrego M, Jimenez B, Antolín S, García-Saenz JA, Corral J, Jerez Y, Trigo J, Urruticoechea A, Colom H, Gonzalo N, Muñoz C, Benito S, Caballero R, Bezares S, Carrasco E, Rojo F, Martín M. Ruiz-Borrego M, et al. Among authors: urruticoechea a. Invest New Drugs. 2019 Feb;37(1):98-108. doi: 10.1007/s10637-018-0614-9. Epub 2018 Jun 9. Invest New Drugs. 2019. PMID: 29948356 Clinical Trial.
Efficacy and safety of dasatinib with trastuzumab and paclitaxel in first line HER2-positive metastatic breast cancer: results from the phase II GEICAM/2010-04 study.
Ocana A, Gil-Martin M, Antolín S, Atienza M, Montaño Á, Ribelles N, Urruticoechea A, Falcón A, Pernas S, Orlando J, Montero JC, Escudero MJ, Benito S, Caballero R, Carrasco E, Rojo F, Pandiella A, Ruiz-Borrego M. Ocana A, et al. Among authors: urruticoechea a. Breast Cancer Res Treat. 2019 Apr;174(3):693-701. doi: 10.1007/s10549-018-05100-z. Epub 2019 Jan 3. Breast Cancer Res Treat. 2019. PMID: 30607629 Clinical Trial.
A Pathology-Based Combined Model to Identify PAM50 Non-luminal Intrinsic Disease in Hormone Receptor-Positive HER2-Negative Breast Cancer.
Pascual T, Martin M, Fernández-Martínez A, Paré L, Alba E, Rodríguez-Lescure Á, Perrone G, Cortés J, Morales S, Lluch A, Urruticoechea A, González-Farré B, Galván P, Jares P, Rodriguez A, Chic N, Righi D, Cejalvo JM, Tonini G, Adamo B, Vidal M, Villagrasa P, Muñoz M, Prat A. Pascual T, et al. Among authors: urruticoechea a. Front Oncol. 2019 Apr 26;9:303. doi: 10.3389/fonc.2019.00303. eCollection 2019. Front Oncol. 2019. PMID: 31106144 Free PMC article.
Efficacy and safety of concurrent trastuzumab plus weekly paclitaxel-FEC as primary therapy for HER2-positive breast cancer in everyday clinical practice.
Pernas S, Gil-Gil M, de Olza MO, Gumà A, Climent F, Petit A, Pla MJ, García-Tejedor A, López-Ojeda A, Falo C, Fernandez-Otega A, Mesia C, Pérez-Martin FJ, Urruticoechea A, Germà JR. Pernas S, et al. Among authors: urruticoechea a. Breast Cancer Res Treat. 2012 Aug;134(3):1161-8. doi: 10.1007/s10549-012-2149-7. Epub 2012 Jul 8. Breast Cancer Res Treat. 2012. PMID: 22772380 Clinical Trial.
Eribulin mesylate in breast cancer.
Verdaguer H, Morilla I, Urruticoechea A. Verdaguer H, et al. Among authors: urruticoechea a. Womens Health (Lond). 2013 Nov;9(6):517-26. doi: 10.2217/whe.13.61. Womens Health (Lond). 2013. PMID: 24161305 Free article.
Effect of a diet and physical activity intervention on body weight and nutritional patterns in overweight and obese breast cancer survivors.
Travier N, Fonseca-Nunes A, Javierre C, Guillamo E, Arribas L, Peiró I, Buckland G, Moreno F, Urruticoechea A, Oviedo GR, Roca A, Hurtós L, Ortega V, Muñoz M, Garrigós L, Cirauqui B, Del Barco S, Arcusa A, Seguí MA, Borràs JM, Gonzalez CA, Agudo A. Travier N, et al. Among authors: urruticoechea a. Med Oncol. 2014 Jan;31(1):783. doi: 10.1007/s12032-013-0783-5. Epub 2013 Dec 6. Med Oncol. 2014. PMID: 24310809 Clinical Trial.
FN14 and GRP94 expression are prognostic/predictive biomarkers of brain metastasis outcome that open up new therapeutic strategies.
Martínez-Aranda A, Hernández V, Guney E, Muixí L, Foj R, Baixeras N, Cuadras D, Moreno V, Urruticoechea A, Gil M, Oliva B, Moreno F, González-Suarez E, Vidal N, Andreu X, Seguí MA, Ballester R, Castella E, Sierra A. Martínez-Aranda A, et al. Among authors: urruticoechea a. Oncotarget. 2015 Dec 29;6(42):44254-73. doi: 10.18632/oncotarget.5471. Oncotarget. 2015. PMID: 26497551 Free PMC article.
83 results